Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Integrated optical driver for interferometric optical gyroscopes.

Tran MA, Komljenovic T, Hulme JC, Kennedy MJ, Blumenthal DJ, Bowers JE.

Opt Express. 2017 Feb 20;25(4):3826-3840. doi: 10.1364/OE.25.003826.

2.

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G, Glackin CA.

Sci Rep. 2016 Nov 23;6:37652. doi: 10.1038/srep37652.

3.

Nicotinic receptor activation augments muscarinic receptor-mediated eccrine sweating but not cutaneous vasodilatation in young males.

Fujii N, Louie JC, McNeely BD, Zhang SY, Tran MA, Kenny GP.

Exp Physiol. 2017 Feb 1;102(2):245-254. doi: 10.1113/EP085916. Epub 2016 Dec 26.

PMID:
27859779
4.

K+ channel mechanisms underlying cholinergic cutaneous vasodilation and sweating in young humans: roles of KCa, KATP, and KV channels?

Fujii N, Louie JC, McNeely BD, Zhang SY, Tran MA, Kenny GP.

Am J Physiol Regul Integr Comp Physiol. 2016 Sep 1;311(3):R600-6. doi: 10.1152/ajpregu.00249.2016. Epub 2016 Jul 20.

5.

Integrated chip-scale Si<sub>3</sub>N<sub>4</sub> wavemeter with narrow free spectral range and high stability.

Xiang C, Tran MA, Komljenovic T, Hulme J, Davenport M, Baney D, Szafraniec B, Bowers JE.

Opt Lett. 2016 Jul 15;41(14):3309-12. doi: 10.1364/OL.41.003309.

PMID:
27420522
6.

Geographical variation in the management of urolithiasis in Australia.

Tran MA, Chak-Lee M, Bariol SV.

ANZ J Surg. 2017 Jun;87(6):509-513. doi: 10.1111/ans.13646. Epub 2016 Jun 3.

PMID:
27261420
7.

Frequency modulated lasers for interferometric optical gyroscopes.

Komljenovic T, Tran MA, Belt M, Gundavarapu S, Blumenthal DJ, Bowers JE.

Opt Lett. 2016 Apr 15;41(8):1773-6. doi: 10.1364/OL.41.001773.

PMID:
27082342
8.

Identification of multisegmental nociceptive afferents that modulate locomotor circuits in the neonatal mouse spinal cord.

Mandadi S, Hong P, Tran MA, Bráz JM, Colarusso P, Basbaum AI, Whelan PJ.

J Comp Neurol. 2013 Aug 15;521(12):2870-87. doi: 10.1002/cne.23321.

PMID:
23436436
9.

Development and use of ceramide nanoliposomes in cancer.

Watters RJ, Kester M, Tran MA, Loughran TP Jr, Liu X.

Methods Enzymol. 2012;508:89-108. doi: 10.1016/B978-0-12-391860-4.00005-7.

PMID:
22449922
10.

Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.

Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M.

Cancer Biol Ther. 2011 Oct 1;12(7):574-85. Epub 2011 Oct 1.

11.

Staff perceptions and organizational factors as predictors of seclusion and restraint on psychiatric wards.

De Benedictis L, Dumais A, Sieu N, Mailhot MP, Létourneau G, Tran MA, Stikarovska I, Bilodeau M, Brunelle S, Côté G, Lesage AD.

Psychiatr Serv. 2011 May;62(5):484-91. doi: 10.1176/ps.62.5.pss6205_0484.

PMID:
21532073
12.

Identification of novel small molecule antimicrobials targeting Mycoplasma bovis.

Soehnlen MK, Tran MA, Lysczek HR, Wolfgang DR, Jayarao BM.

J Antimicrob Chemother. 2011 Mar;66(3):574-7. doi: 10.1093/jac/dkq503. Epub 2011 Jan 17.

PMID:
21393230
13.

Endogenous extracellular serotonin modulates the spinal locomotor network of the neonatal mouse.

Dunbar MJ, Tran MA, Whelan PJ.

J Physiol. 2010 Jan 1;588(Pt 1):139-56. doi: 10.1113/jphysiol.2009.177378. Epub 2009 Nov 2.

14.

Use of liposomes as drug delivery vehicles for treatment of melanoma.

Tran MA, Watts RJ, Robertson GP.

Pigment Cell Melanoma Res. 2009 Aug;22(4):388-99. doi: 10.1111/j.1755-148X.2009.00581.x. Epub 2009 May 22. Review.

15.

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP.

Cancer Res. 2008 Sep 15;68(18):7638-49. doi: 10.1158/0008-5472.CAN-07-6614.

16.

Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL.

J Clin Invest. 2008 Sep;118(9):3109-22. doi: 10.1172/JCI34120.

17.

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.

Tran MA, Smith CD, Kester M, Robertson GP.

Clin Cancer Res. 2008 Jun 1;14(11):3571-81. doi: 10.1158/1078-0432.CCR-07-4881.

18.

Dopaminergic modulation of spinal neuronal excitability.

Han P, Nakanishi ST, Tran MA, Whelan PJ.

J Neurosci. 2007 Nov 28;27(48):13192-204.

19.

In vivo pharmacodynamic interactions between two drugs used in orthostatic hypotension--midodrine and dihydroergotamine.

Jourdan G, Verwaerde P, Pathak A, Tran MA, Montastruc JL, Senard JM.

Fundam Clin Pharmacol. 2007 Feb;21(1):45-53.

PMID:
17227444
20.
21.

Blood pressure and heart rate variability in patients with essential hyperhidrosis.

Senard JM, Simonetta-Moreau M, Tran MA.

Clin Auton Res. 2003 Aug;13(4):281-5.

PMID:
12955553
22.

Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40.

Li PP, Naknanishi A, Tran MA, Ishizu K, Kawano M, Phillips M, Handa H, Liddington RC, Kasamatsu H.

J Virol. 2003 Jul;77(13):7527-38.

23.

In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission.

Vernejoul F, Damase-Michel C, Montastruc JL, Tran MA.

Eur J Pharmacol. 2002 May 31;444(3):197-202.

PMID:
12063080
24.

Alpha2 -adrenoceptor function in arterial hypertension associated with obesity in dogs fed a high-fat diet.

Pelat M, Verwaerde P, Tran MA, Montastruc JL, Senard JM.

J Hypertens. 2002 May;20(5):957-64.

PMID:
12011657
25.

Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.

Pelat M, Verwaerde P, Tran MA, Berlan M, Senard JM, Montastruc JL.

Fundam Clin Pharmacol. 2001 Aug;15(4):239-45.

PMID:
11564130
26.

[Atropine. Principles and rules of utilization].

Pathak A, Tran MA, Montastruc JL.

Rev Prat. 2001 Jan 15;51(1):59-63. French. No abstract available.

PMID:
11234098
27.

Fluoxetine-induced pressor response in freely moving rats: a role for vasopressin and sympathetic tone.

Lazartigues E, Brefel-Courbon C, Bagheri H, Costes S, Gharib C, Tran MA, Senard JM, Montastruc JL.

Fundam Clin Pharmacol. 2000 Sep-Oct;14(5):443-51.

PMID:
11129084
28.

Role of simian virus 40 Vp1 cysteines in virion infectivity.

Li PP, Nakanishi A, Tran MA, Salazar AM, Liddington RC, Kasamatsu H.

J Virol. 2000 Dec;74(23):11388-93.

29.

Characterization of the central muscarinic cholinoceptors involved in the cholinergic pressor response in anesthetized dogs.

Pelat M, Lazartigues E, Tran MA, Gharib C, Montastruc JL, Montastruc P, Rascol O.

Eur J Pharmacol. 1999 Aug 27;379(2-3):117-24.

PMID:
10497897
30.

[Reduction of the pressor effect of fluoxetine after V1A-vasopressin receptor blockade in the conscious rats].

Lazartigues E, Costes S, Brefel-Courbon C, Gharib C, Tran MA, Senard JM, Montastruc JL.

Arch Mal Coeur Vaiss. 1999 Aug;92(8):985-9. French.

PMID:
10486651
31.

Spontaneously hypertensive rats cholinergic hyper-responsiveness: central and peripheral pharmacological mechanisms.

Lazartigues E, Brefel-Courbon C, Tran MA, Montastruc JL, Rascol O.

Br J Pharmacol. 1999 Aug;127(7):1657-65.

32.

Water drinking and the heart.

Senard JM, Brefel C, Carel C, Tran MA, Montastruc JL.

Lancet. 1999 Jun 5;353(9168):1971-2. No abstract available.

PMID:
10371595
33.

Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.

Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, Montastruc JL, Rascol O.

Eur J Pharmacol. 1998 Nov 13;361(1):61-71.

PMID:
9851542
34.

Endogenous central cholinergic systems and baroreflex modulation in the conscious dog.

Lazartigues E, Tran MA, Brefel-Courbon C, Montastruc JL, Rascol O.

Fundam Clin Pharmacol. 1998;12(6):643-5.

PMID:
9818298
35.

[Atropine].

Montastruc JL, Tran MA.

Rev Prat. 1998 Jan 1;48(1):85-7. French. No abstract available.

PMID:
9781216
36.

Effect of losartan on afferent nerve stimulation.

Damase-Michel C, Tran MA, Montastruc JL, Montastruc P.

Eur J Pharmacol. 1998 Aug 21;355(2-3):125-32.

PMID:
9760026
37.

[Functional decoupling of left ventricular beta-adrenoceptor in a canine model of obesity-hypertension].

Cabrol P, Galinier M, Fourcade J, Verwaerde P, Massabuau P, Tran MA, Montastruc JL, Bounhoure JP, Fauvel JM, Sénard JM.

Arch Mal Coeur Vaiss. 1998 Aug;91(8):1021-4. French.

PMID:
9749157
38.

Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.

Montastruc JL, Pelat M, Verwaerde P, Brefel-Courbon C, Tran MA, Blin O, Rascol O, Senard JM.

Fundam Clin Pharmacol. 1998;12(4):398-402.

PMID:
9711461
39.

Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release.

Allal C, Lazartigues E, Tran MA, Brefel-Courbon C, Gharib C, Montastruc JL, Rascol O.

Eur J Pharmacol. 1998 May 8;348(2-3):191-8.

PMID:
9652334
40.

[Autonomic nervous system abnormalities in the initial phase of insulin resistance syndrome. Value of the study of variability of cardiac rate and blood pressure on a model of nutritional obesity].

Verwaerde P, Galinier M, Fourcade J, Massabuau P, Galitzky J, Senard JM, Tran MA, Berlan M, Montastruc JL.

Arch Mal Coeur Vaiss. 1997 Aug;90(8):1151-4. French.

PMID:
9404426
41.

Effects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension.

Verwaerde P, Tran MA, Montastruc JL, Senard JM, Portolan G.

Fundam Clin Pharmacol. 1997;11(6):567-75.

PMID:
9444525
42.

Effects of octreotide on experimental neurogenic orthostatic hypotension in anaesthetized dogs.

Bordet R, Verwaerde P, Tran MA, Marques MA, Montastruc JL, Senard JM.

Fundam Clin Pharmacol. 1997;11(3):237-44.

PMID:
9243255
43.

A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.

Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL.

Clin Neuropharmacol. 1996 Oct;19(5):420-7.

PMID:
8889285
44.

[Effects of octreotide on experimental orthostatic neurogenic hypotension].

Verwaerde P, Bordet R, Portolan G, Tran MA, Marques MA, Montastruc JL, Sénard JM.

Arch Mal Coeur Vaiss. 1996 Aug;89(8):1097-1101. French.

PMID:
8949386
45.

Spectral analysis of blood pressure and heart rate, catecholamine and neuropeptide Y plasma levels in a new model of neurogenic orthostatic hypotension in dog.

Verwaerde P, Senard JM, Mazerolles M, Tran MA, Damase-Michel C, Montastruc JL, Montastruc P.

Clin Auton Res. 1996 Apr;6(2):75-82.

PMID:
8726091
46.

A study of tolerance to apomorphine.

Montastruc JL, Llau ME, Senard JM, Tran MA, Rascol O, Montastruc P.

Br J Pharmacol. 1996 Mar;117(5):781-6.

47.

Effects of pentobarbital and etomidate on plasma catecholamine levels and spectral analysis of blood pressure and heart rate in dogs.

Mazerolles M, Senard JM, Verwaerde P, Tran MA, Montastruc JL, Virenque C, Montastruc P.

Fundam Clin Pharmacol. 1996;10(3):298-303.

PMID:
8836704
48.

Central cardiovascular effects of acetylcholine in the conscious dog.

Brefel C, Lazartigues E, Tran MA, Gauquelin G, Geelen G, Gharib C, Montastruc JL, Montastruc P, Rascol O.

Br J Pharmacol. 1995 Oct;116(4):2175-82.

49.

Involvement of renal dopaminergic system in experimental neurogenic arterial hypertension.

Sanchez P, Damase-Michel C, Tran MA, Montastruc JL.

Hypertens Res. 1995 Jun;18 Suppl 1:S187-90.

50.

Effects of dopaminergic drugs on the sympathoadrenal system.

Damase-Michel C, Montastruc JL, Tran MA.

Hypertens Res. 1995 Jun;18 Suppl 1:S119-24.

Supplemental Content

Support Center